Acronym | Test |
---|---|
EIA | Enzyme immunoassay |
FISH | Fluorescence in-situ hybridization |
ICC | Immunocytochemistry |
ICMA | Immunochemiluminometric assay |
IHC | Immunohistochemistry |
IRMA | Immunoradiometric assay |
MEIA | Microparticle enzyme immunoassay |
PCR | Polymerase chain reaction |
RIA | Radioimmunoassay |
RT-PCR | Reverse transcriptase polymerase chain reaction |
Profile Contents
1. Acid phosphatase, total and prostatic
2. Adrenocorticotropic hormone
3. Alpha fetoprotein
4. AML1/ETO translocation
5. B-cell gene rearrangement
6. BCL-1/JH gene rearrangement
7. BCL-2 translocation
8. BCR/ABL gene rearrangement
9. Beta human chorionic gonadotropin
10. Beta-2 microglobulin
11. Bladder tumor antigen
12. BRCA Analysis
13. Calcitonin
14. Cancer antigen 125
15. Cancer antigen 15-3
16. Cancer antigen 19-9
17. Cancer antigen 27.29
18. Carcinoembryonic antigen
19. Cathepsin D
20. CBFB/MYH11 fusion protein
21. CD 117, c-kit
22. CD 20
23. CD 25
24. CD 33
25. CD 52
26. Chromosome 18q assay
27. Colaris
28. Colaris AP
29. Cyclin-D1
30. E-cadherin
31. Epidermal growth factor
receptor
32. Estrogen/progesterone
receptor
33. Fecal globin
34. FLT 3 mutation
35. HER-2/neu
36. 5-HIAA
37. Human papillomavius hybrid
capture
38. IgVH mutation analysis
39. Immunocyt
40. Kappa/lambda light chain
41. LAP
42. Lipid associated sialic
acid
43. Melaris
44. MIB-1 antibody
45. Micrometastasis detection
46. Microsatellite
instability
47. MLH1, MSH2, MSH6
mutations
48. Neuron specific enolase
49. Nuclear matrix proteins
50. Oncotype Dx
51. p53 tumor suppressor gene
52. PML/RARA translocation
53. PreGen-26
54. PreGen-Plus
55. Prostate-specific antigen
56. T-cell recepter gene
rearrangment
57. TEL/AML1 gene fusion
58. Thyroglobulin
59. Tumor antigen 90 immune
complex
60. Urokinase plasminogen
activator
61. Urovysion
62. ZAP-70
Test name | Acid phosphatase, total and prostatic |
---|---|
Other names | PAP |
Description | Elevated levels of this enzyme are found in patients with metastatic prostate cancer. PAP determination, in conjunction with PSA measurements, is useful in assessing the prognosis of prostate cancer. Concentrations of both the prostatic and nonprostatic forms of acid phosphatase may be differentiated using tartrate. The activity of the prostatic form of the enzyme is inhibited in the presence of tartrate. |
Purpose | Prognostic, recurrence, monitoring |
Availability | Commercial laboratories, academic hospitals |
Specimen | Serum, frozen |
Methodology | ICMA Spectrophotometry - alpha-naphthol phosphate substrate with tartrate inhibition for prostatic AcP determination |
Cancers | Prostate cancer |
Clinical use(s) a) Routine: |
|
Source of information | LabCorp, Specialty Laboratories, UpToDate™ Web sites |
Exploratory Medline search (5/25/05) |
|
Test name | Adrenocorticotropic hormone |
---|---|
Other names | ACTH hormone |
Description | ACTH has been used in diagnosing disorders of the hypothalamicpituitary system. It is useful in the differential diagnosis of Cushing syndrome, ectopic ACTH syndrome, Addison disease, hypopituitarism, and ACTH-producing pituitary tumors (e.g., Nelson syndrome). The most common causes of ectopic ACTH syndrome are small (oat)-cell carcinomas, carcinoid tumors, particularly bronchial carcinoids, islet cell tumors, and pulmonary tumorlets. |
Purpose | Diagnostic |
Availability | Commercial laboratories, academic hospitals |
Specimen | plasma |
Methodology | ICMA |
Cancers | pituitary, adrenal |
Other cancers | Carcinoid, thyroid, pulminary, pancreas |
Clinical use(s) a) Routine: |
|
Source of information | Quest Diagnostics, LabCorps, Specialty Laboratories, UpToDate™ |
Exploratory Medline search (5/26/05) |
|
Test name | Alpha-Fetoprotein |
---|---|
Other names | AFP |
Description | Elevated serum AFP levels are most closely associated with nonseminomatous testicular cancer and hepatocellular cancer. The rate of clearance from serum after treatment is an indicator of the effectiveness of therapy. Conversely, the growth rate of progressive disease can be monitored by serially measuring serum AFP concentrations over time. |
Purpose | Secondary prevention, prognostic, recurrence, monitoring |
Availability | Commercial laboratories, academic hospitals |
Specimen | Serum protein |
Methodology | ICMA |
Cancers | Non-seminomatous testicular, hepatocellular |
Other cancers | AFP may also be elevated in malignant germ cell tumors of ovary and testis, gastrointestinal, pancreatic, pulmonary cancer. |
Clinical use(s) a) Routine: |
|
Clinical use(s) b) Investigational |
|
Source of information | Quest Diagnostics, LabCorp, Specialty Laboratories Web sites |
Exploratory Medline search (5/12/05) |
|
Test name | AML1/ETO translocation |
---|---|
Other names | t(8:21) |
Description | The translocation t(8;21)(q22;q22) is one of the most common structural chromosomal aberrations in patients with Acute Myeloid Leukemia (AML). AML with t(8;21) has a mean onset age of about 30 years and is most common in children and younger adults; it is relatively rare in elderly patients. The presence of t(8;21) is associated with the highest complete remission rate (90 percent) and the highest probability (50 percent-70 percent) of remaining in complete remission at 5 years. However, the disease may become resistant to therapy upon relapse. |
Purpose | Diagnostic, prognostic, recurrence, monitoring |
Availability | Commercial laboratories, academic hospitals |
Specimen | Whole blood, bone marrow |
Methodology | PCR |
Cancers | Acute myeloid leukemia |
Clinical use(s) a) Routine: |
|
Source of information | Quest Diagnostics, LabCorp, UpToDate™ |
Exploratory Medline search (6/01/05) |
|
Test name | B-cell gene rearrangement |
---|---|
Description | These additional studies are used to establish a definitive diagnosis. They include molecular analysis of tumor material using PCR technology to identify gene rearrangements known to be associated with B-cell malignancies. Additionally the special tests can sometimes help to establish both the lineage and the presence of prognostically significant subtypes of malignant lymphoma. |
Purpose | Diagnostic, prognostic, recurrence |
Availability | Commercial laboratories, academic hospitals |
Specimen | Whole blood, bone marrow, or tissue |
Methodology | PCR |
Cancers | B-cell malignancies |
Clinical use(s) a) Routine: |
|
Source of information | Quest Diagnostics, LabCorps Web sites |
Exploratory Medline search (6/01/05) |
|
Test name | bcl-1/JH t(11;14) Gene Rearrangement |
---|---|
Other names | t(11;14) |
Description | The t(11;14)(q13;q32) rearrangement causes deregulation of the bcl-1 gene and over-expression of cyclin D1, which may in turn lead to lymphoma genesis. The bcl-1 translocation is specific for mantle cell lymphoma |
Purpose | Diagnostic, prognostic, monitoring |
Availability | Commercial laboratories, academic hospitals |
Specimen | Whole blood, bone marrow, tissue |
Methodology | PCR |
Cancers | Mantle cell lymphoma |
Clinical use(s) a) Routine: |
|
Source of information | Quest Diagnostics, LabCorp |
Exploratory Medline search (6/01/05) |
|
Test name | BCL-2 translocation |
---|---|
Other names | t(14:18) |
Description | The bcl-2 gene translocation, t(14;18), is the rearrangement of the bcl-2 proto-oncogene on chromosome 18 with the immunoglobulin heavy chain region on chromosome 14. The bcl-2 translocation is a characteristic of Bcell lymphomas. It is observed in 70 to 90 percent of follicular non-Hodgkin B-cell lymphomas, 20 to 30 percent of large diffuse B-cell lymphomas, and 50 percent of undifferentiated B-cell lymphomas, but not in other lymphomas. |
Purpose | Diagnostic, prognostic, recurrence, monitoring |
Availability | Commercial laboratories, academic hospitals |
Specimen | Blood, marrow, tissue |
Methodology | PCR |
Cancers | B-cell lymphomas |
Clinical use(s) a) Routine: |
|
Source of information | Quest Diagnostics, UpToDate™ Web sites |
Exploratory Medline search (6/01/05) |
|
Test name | BCR-ABL |
---|---|
Other names | Philadelphia chromosome |
Description | Bcr/abl fusion gene, formed by rearrangement of the breakpoint cluster region (bcr) on chromosome 22 with the c-abl proto-oncogene on chromosome 9, is present in 95 percent of CML patients and 30 percent of ALL patients. Identification of bcr/abl rearrangement is important for the diagnosis of CML, whereas in ALL, presence of bcr/abl is associated with poor prognosis and may warrant more aggressive therapy. In both diseases, increasing levels of bcr/abl may be associated with clinical progression. |
Purpose | Diagnostic, prognostic, recurrence, monitoring |
Availability | Commercial laboratories, academic hospitals |
Specimen | Whole blood, bone marrow RNA |
Methodology | PCR, FISH |
Cancers | Chronic Myelogenous Leukemia (CML), Acute Lymphocytic Leukemia (ALL) |
Clinical use(s) a) Routine: |
|
Source of information | Quest Diagnostics, LabCorp, Specialty Labs Web sites, UpToDate™ |
Exploratory Medline search (5/12/05) |
|
Test name | Beta human chorionic gonadotropin |
---|---|
Other names | beta-HCG |
Description | beta-hCG is detectable in the serum of 70 percent of patients with nonseminomatous germ-cell tumors. Patients with a prolonged half life of beta -hCG (>3.5 days) have an inferior overall and disease-free survival and may be candidates for high dose chemotherapy. In germ cell tumors in the male, beta-hCG and alpha-fetoprotein are both useful tumor markers. |
Purpose | Diagnostic, recurrence, monitoring |
Availability | Commercial laboratories, academic hospitals |
Specimen | Serum |
Methodology | ICMA |
Cancers | Germ cell tumors (e.g., teratoma, struma ovarii, dysgerminoma, yolk sac tumor, embryonal carcinoma, and choriocarcinoma) |
Other cancers | Lung, pancreas, liver, stomach |
Clinical use(s) a) Routine: |
|
Clinical use(s) b) Investigational |
|
Source of information | LabCorp, UpToDate™, Specialty Labs Web sites |
Exploratory Medline search (6/01/05) |
|
Test name | Beta 2-microglobulin |
---|---|
Description | Beta 2-microglobulin is increased nonspecifically in active chronic lymphocytic leukemia in which there is increased lymphocyte turnover. Elevated levels of beta 2-microglobulin can be found in cerebral spinal fluid (relative to serum) in acute lymphoblastic leukemia, lymphoma, and other lymphoproliferative disorders. (Lymphoproliferative disorders refers to a group of malignant diseases involving the lymphoid cells and cells from the reticuloendothelial system, including lymphoma and posttransplant lymphoproliferative disorder). Increased serum concentrations of beta 2-microglobulin are good predictors of complete response and time to treatment failure in low-grade lymphoma. |
Purpose | Diagnostic, prognostic |
Availability | Commercial laboratories, academic hospitals |
Specimen | Serum |
Methodology | ICMA |
Cancers | Lymphoma, Hodgkin’s and Non-Hodgkin’s Lymphoma |
Other cancers | Multiple myeloma, chronic lymphocytic leukemia, and other indolent lymphomas |
Clinical use(s) a) Routine: |
|
Source of information | LabCorp, Specialty Labs, UpToDate™ |
Exploratory Medline search (6/01/05) |
|
Test name | Bladder Tumor Antigen |
---|---|
Other names | BTA |
Description | A biomarker that is currently being investigated for use in surveillance following initial treatment of superficial bladder cancer. |
Purpose | Recurrence, monitoring |
Availability | Commercial laboratories, academic hospitals |
Specimen | Urine |
Methodology | Cytology, EIA |
Cancers | Bladder |
Other cancers | Kidney and ureter |
Clinical use(s) b) Investigational |
|
Source of information | Quest Diagnostics, LabCorp, UpToDate™ Web sites |
Exploratory Medline search (6/01/05) |
|
Test name | BRCA Analysis |
---|---|
Other names | BRCA1, BRCA2 |
Description | BRCA1 and BRCA2 are two susceptibility genes for breast cancer that are inherited in an autosomal dominant fashion and account for one-fifth of the familial risk of breast cancer. BRCA mutations are found in between 1 and 3.3 percent of American women with breast cancer who are unselected for family history. However, the prevalence of a deleterious BRCA1 or BRCA2 mutation in women of Ashkenazi Jewish (Eastern European) descent is approximately 2 percent. |
Purpose | Primary prevention, prognostic |
Availability | Commercial laboratories, academic hospitals |
Specimen | Whole blood |
Methodology | PCR |
Cancers | Breast, ovarian |
Other cancers | Prostate, lymphoma, melanoma, cancers of the gallbladder, pancreas, stomach |
Clinical use(s) a) Routine: |
|
Source of information | Quest, LabCorp, UpToDate™ Web sites |
Exploratory Medline search (8/02/05) |
|
Test name | Calcitonin |
---|---|
Description | High concentrations of calcitonin occur in patients with malignant parafollicular or C-cell tumors of the thyroid gland. The doubling time of serum levels of this hormone correlates with recurrence of tumors. |
Purpose | Secondary prevention, diagnostic, prognostic, recurrence |
Availability | Commercial laboratories, academic hospitals |
Specimen | Serum, frozen |
Methodology | ICMA |
Cancers | Thyroid gland |
Other cancers | Lung, breast, carcinoids, islet cell tumors, APUDomas |
Clinical use(s) a) Routine: |
|
Clinical use(s) b) Investigational |
|
Source of information | LabCorps, Specialty Laboratories, Quest, UpToDate™ Web sites |
Exploratory Medline search (08/02/05) |
|